de Magalhães interview: “Still lots of work to do”

Professor João Pedro de Magalhães on different areas of Longevity.

Continuing our series of interviews with our Advisory Panel members, we caught up with João Pedro de Magalhães, PhD, Professor at the Institute of Ageing and Chronic Disease at the University of Liverpool.

Longevity.Technology: João Pedro is a scientist and futurist whose Human Ageing Genomic Resources database is an important tool for studying the genetics of human aging. With his eye on the spread of Longevity areas before him, we asked João Pedro which areas warrant more attention.

João Pedro de Magalhães: I think the mechanisms of aging seems to have disappeared from the radar a bit. There is a lot of focus on Longevity manipulations and interventions, but I think the field has kind of focussed less on understanding the process of aging.

Longevity.Technology: What about education on Longevity for investors?

João Pedro de Magalhães: I still think there’s a lot we need to do in terms of educating investors, yes, although of course there are now more investors and some of them are more knowledgeable about Longevity and aging. Nonetheless, still lots of work to do and your efforts in this are very much appreciated.

Longevity.Technology: Which areas will always underpin Longevity, do you think? Might changes be coming?

João Pedro de Magalhães: Immunotherapy is very much focused on cancer, and I don’t think it’s going to go away any time soon. Senolytics are fashionable now, but they weren’t sometime ago, so they may come and go, hard to say. And there will likely be other pharmacological interventions that will be of interest and may become more popular down the line. I think genetherapy will grow in popularity, actually, it’s still not very mainstream.

Check out our earlier interview with Advisory Panel member and LyGenesis CEO Michael Hufford.

Eleanor Garth
Staff Writer and Community Manager Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Latest articles

Evidence for tenth hallmark of aging increases with new paper

Is ten the new nine? Additional research adds weight to the argument that extracellular matrix stiffening should be considered the tenth hallmark of aging. Since...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...

GDF15 protects from age‐related metabolic phenotypes

A recent study shows an important role for GDF15 in preventing aging-induced metabolic phenotypes by modulating systemic inflammatory responses in humans and mice. Dysfunction of...